Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Jiangbing Zhou is active.

Publication


Featured researches published by Jiangbing Zhou.


Proceedings of the National Academy of Sciences of the United States of America | 2007

Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance

Jiangbing Zhou; Julia Wulfkuhle; Hao Zhang; Peihua Gu; Yanqin Yang; Jianghong Deng; Joseph B. Margolick; Lance A. Liotta; Emanuel Petricoin; Ying Zhang

Side-population (SP) cells within cancers and cell lines are rare cell populations known to enrich cancer stem-like cells. In this study, we characterized SP cells from the human breast cancer cell line MCF7 as a model for cancer stem-like cells. Compared with non-SP cells, MCF7 SP cells had higher colony-formation ability in vitro and greater tumorigenicity in vivo, suggesting that MCF7 SP cells enrich cancer stem-like cells. cDNA microarray analysis of the SP cells indicated higher expression of ATP-binding cassette transporters and genes involved in quiescence, which were confirmed by quantitative RT-PCR and flow cytometry cell cycle analysis. To identify signal pathways important for cancer stem-like cells, we analyzed cDNA microarray data and identified nine pathways that were altered in the SP cells. To analyze the protein signaling networks, we used reverse-phase signaling pathway protein microarray technology and identified three signaling proteins that are significantly different between MCF7 SP and non-SP cells. Notably, signaling of phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR), signal transduction and activator of transcription (STAT3), and phosphatase and tensin homolog (PTEN) was confirmed to be critical for MCF7 SP cell survival and proliferation by pathway specific inhibitors, selected gene knockdown, and in vivo tumorigenicity assay. The STAT3 pathway was found to be positively regulated by mTOR signaling, whereas PTEN served as a negative regulator of both STAT3 and mTOR signaling. This study suggests the existence of prosurvival signaling pathways critical for cancer stem-like cell maintenance, which could be selectively targeted for inhibiting cancer stem-like cells for improved treatment.


Nature Materials | 2012

Biodegradable poly(amine-co-ester) terpolymers for targeted gene delivery

Jiangbing Zhou; Jie Liu; Christopher J. Cheng; Toral R. Patel; Caroline E. Weller; Joseph M. Piepmeier; Zhaozhong Jiang; W. Mark Saltzman

Many synthetic polycationic vectors for non-viral gene delivery show high efficiency in vitro, but their usually excessive charge density makes them toxic for in vivo applications. Here we describe the synthesis of a series of high molecular weight terpolymers with low charge density, and show that they exhibit efficient gene delivery, some surpassing the efficiency of the commercial transfection reagents Polyethylenimine and Lipofectamine 2000. The terpolymers were synthesized via enzyme-catalyzed copolymerization of lactone with dialkyl diester and amino diol, and their hydrophobicity adjusted by varying the lactone content and by selecting a lactone comonomer of specific ring size. Targeted delivery of the pro-apoptotic TRAIL gene to tumour xenografts by one of the terpolymers results in significant inhibition of tumour growth, with minimal toxicity both in vitro and in vivo. Our findings suggest that the gene delivery ability of the terpolymers stems from their high molecular weight and increased hydrophobicity, which compensates for their low charge density.


Advanced Drug Delivery Reviews | 2012

Polymeric nanoparticles for drug delivery to the central nervous system

Toral R. Patel; Jiangbing Zhou; Joseph M. Piepmeier; W. Mark Saltzman

The central nervous system (CNS) poses a unique challenge for drug delivery. The blood-brain barrier significantly hinders the passage of systemically delivered therapeutics and the brain extracellular matrix limits the distribution and longevity of locally delivered agents. Polymeric nanoparticles represent a promising solution to these problems. Over the past 40years, substantial research efforts have demonstrated that polymeric nanoparticles can be engineered for effective systemic and local delivery of therapeutics to the CNS. Moreover, many of the polymers used in nanoparticle fabrication are both biodegradable and biocompatible, thereby increasing the clinical utility of this strategy. Here, we review the major advances in the development of polymeric nanoparticles for drug delivery to the CNS.


Glycobiology | 2008

Lectin microarrays identify cell-specific and functionally significant cell surface glycan markers

Shengce Tao; Yu Li; Jiangbing Zhou; Jiang Qian; Ronald L. Schnaar; Ying Zhang; Irwin J. Goldstein; Heng Zhu; Jonathan P. Schneck

Glycosylation is among the most complex posttranslational modifications with an extremely high level of diversity that has made it refractory to high-throughput analyses. Despite its resistance to high-throughput techniques, glycosylation is important in many critical cellular processes that necessitate a productive approach to their analysis. To facilitate studies in glycosylation, we developed a high-throughput lectin microarray for defining mammalian cell surface glycan signatures. Using the lectin microarray we established a binary analysis of cell binding and hierarchical organization of 24 mammalian cell lines. The array was also used to document changes in cell surface glycosylation during cell development and differentiation of primary murine immune system cells. To establish the biological and clinical importance of glycan signatures, the lectin microarray was applied in two systems. First, we analyzed the cell surface glycan signatures and were able to predict mannose-dependent tropism using a model pathogen. Second, we used the glycan signatures to identify novel lectin biomarkers for cancer stem-like cells in a murine model. Thus, lectin microarrays are an effective tool for analyzing diverse cell processes including cell development and differentiation, cell-cell communication, pathogen-host recognition, and cell surface biomarker identification.


Biomaterials | 2012

Octa-functional PLGA nanoparticles for targeted and efficient siRNA delivery to tumors.

Jiangbing Zhou; Toral R. Patel; Michael Fu; James P. Bertram; W. Mark Saltzman

Therapies based on RNA interference, using agents such as siRNA, are limited by the absence of safe, efficient vehicles for targeted delivery in vivo. The barriers to siRNA delivery are well known and can be individually overcome by addition of functional modules, such as conjugation of moieties for cell penetration or targeting. But, so far, it has been impossible to engineer multiple modules into a single unit. Here, we describe the synthesis of degradable nanoparticles that carry eight synergistic functions: 1) polymer matrix for stabilization/controlled release; 2) siRNA for gene knockdown; 3) agent to enhance endosomal escape; 4) agent to enhance siRNA potency; 5) surface-bound PEG for enhancing circulatory time; and surface-bound peptides for 6) cell penetration; 7) endosomal escape; and 8) tumor targeting. Further, we demonstrate that this approach can provide prolonged knockdown of PLK1 and control of tumor growth in vivo. Importantly, all elements in these octa-functional nanoparticles are known to be safe for human use and each function can be individually controlled, giving this approach to synthetic RNA-loaded nanoparticles potential in a variety of clinical applications.


Proceedings of the National Academy of Sciences of the United States of America | 2013

Highly penetrative, drug-loaded nanocarriers improve treatment of glioblastoma

Jiangbing Zhou; Toral R. Patel; Rachael W. Sirianni; Garth W. Strohbehn; Ming-Qiang Zheng; Nha Duong; Thomas Schafbauer; Anita Huttner; Yiyun Huang; Richard E. Carson; Ying Zhang; David J. Sullivan; Joseph M. Piepmeier; W. Mark Saltzman

Current therapy for glioblastoma multiforme is insufficient, with nearly universal recurrence. Available drug therapies are unsuccessful because they fail to penetrate through the region of the brain containing tumor cells and they fail to kill the cells most responsible for tumor development and therapy resistance, brain cancer stem cells (BCSCs). To address these challenges, we combined two major advances in technology: (i) brain-penetrating polymeric nanoparticles that can be loaded with drugs and are optimized for intracranial convection-enhanced delivery and (ii) repurposed compounds, previously used in Food and Drug Administration-approved products, which were identified through library screening to target BCSCs. Using fluorescence imaging and positron emission tomography, we demonstrate that brain-penetrating nanoparticles can be delivered to large intracranial volumes in both rats and pigs. We identified several agents (from Food and Drug Administration-approved products) that potently inhibit proliferation and self-renewal of BCSCs. When loaded into brain-penetrating nanoparticles and administered by convection-enhanced delivery, one of these agents, dithiazanine iodide, significantly increased survival in rats bearing BCSC-derived xenografts. This unique approach to controlled delivery in the brain should have a significant impact on treatment of glioblastoma multiforme and suggests previously undescribed routes for drug and gene delivery to treat other diseases of the central nervous system.


Cancer Journal | 2012

Novel Delivery Strategies for Glioblastoma

Jiangbing Zhou; Kofi-Buaku Atsina; Benjamin T. Himes; Garth W. Strohbehn; W. Mark Saltzman

AbstractBrain tumors—particularly glioblastoma multiforme—pose an important public health problem in the United States. Despite surgical and medical advances, the prognosis for patients with malignant gliomas remains grim: current therapy is insufficient with nearly universal recurrence. A major reason for this failure is the difficulty of delivering therapeutic agents to the brain: better delivery approaches are needed to improve treatment. In this article, we summarize recent progress in drug delivery to the brain, with an emphasis on convection-enhanced delivery of nanocarriers. We examine the potential of new delivery methods to permit novel drug- and gene-based therapies that target brain cancer stem cells and discuss the use of nanomaterials for imaging of tumors and drug delivery.


Cell Cycle | 2008

Cancer stem cells: Models, mechanisms and implications for improved treatment.

Jiangbing Zhou; Ying Zhang

Cancer stem cell research has drawn a lot of attention recently. The importance of cancer stem cell research lies in the possibility of providing new approaches for improved understanding of cancer biology and cancer treatment. However, cancer stem cell research is still at its infancy. In this review, we will discuss the concept of cancer stem cells and the commonly used approaches for isolating or enriching cancer stem cells. We then review the common features of cancer stem cells including resistance to cancer drugs and stresses such as hypoxia and radiation. We also summarize signaling pathways which might be preferentially important for cancer stem cells. Finally, we will propose a new Yin-Yang model of cancer stem cells and discuss the possibility of developing new drugs that target cancer stem cells for improved treatment of cancer.


Biotechnology and Applied Biochemistry | 2001

A rapid method for detecting conformational changes during differentiation and apoptosis of HL60 cells by Fourier-transform infrared spectroscopy

Jiangbing Zhou; Zhao Wang; Suqing Sun; Ming-Jie Liu; Hongjun Zhang

The conformational changes of HL60 cells during differentiation and apoptosis are still not clearly understood. This study uses a new method, Fourier‐transform infrared (FT‐IR) spectroscopy, to analyse the changes of HL60 cells. We detected several differences among normal HL60 cells, differentiated cells induced by all‐trans retinoic acid (ATRA) and PMA, and apoptotic cells induced by vircristine (VCR). The results suggest that the α‐helix content of the membrane protein of differentiated HL60 cells induced by ATRA and PMA increased, and that the β‐sheet content of membrane proteins of apoptotic cells induced by VCR also increased. Also, C–O(H)‐stretching modes of serine, threonine and tyrosine residues of cell proteins were shown to be distinctly different, but no significant differences were detected between cells differentiated along different lineages by ATRA and PMA.


Antimicrobial Agents and Chemotherapy | 2007

Pyrrolidine dithiocarbamate and diethyldithiocarbamate are active against growing and nongrowing persister Mycobacterium tuberculosis.

Sean T. Byrne; Peihua Gu; Jiangbing Zhou; Steven M. Denkin; Curtis R. Chong; David J. Sullivan; Jun O. Liu; Ying Zhang

ABSTRACT Diethyldithiocarbamate (DETC) and pyrrolidine dithiocarbamate (PDTC) were highly active against tubercle bacilli, with MICs of 8 μg/ml and 0.13 μg/ml, respectively. DETC and PDTC were active against old cultures, enhanced pyrazinamide or pyrazinamide/rifampin activity, and had serum inhibitory titers of 1:2 and 1:4, respectively, in mice given 100 mg/kg orally.

Collaboration


Dive into the Jiangbing Zhou's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Ying Zhang

Johns Hopkins University

View shared research outputs
Top Co-Authors

Avatar

Toral R. Patel

University of Texas Southwestern Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Peihua Gu

Johns Hopkins University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge